LEGEND BIOTECH CORP-ADR (LEGN)

Company Profile

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications. The company is headquartered in Somerset, New Jersey and currently employs 1,390 full-time employees. The company went IPO on 2020-06-04. The firm is developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), is a CAR-T cell therapy for the treatment of multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. The company is also developing an allogeneic gamma delta CAR-T product candidate targeting B-cell maturation antigen for MM.

Company Info

LEGEND BIOTECH CORP-ADR

2101 Cottontail Lane

Somerset NEW JERSEY 08873

P: 17323175050

CEO: Ying Huang

Employees: 1390

Website: https://investors.legendbiotech.com/